Rallybio Q2 net loss $18.6M; cash $137.8M; CEO transition to Stephen Uden

Rallybio Corp

2023-Q2 EPS reported -$0.89

Net loss $18.6M ($0.46/sh) vs $17.6M ($0.57/sh) in Q2 2022; R&D expense $13.1M, up from $10.1M.
Cash, equivalents and marketable securities $137.8M as of June 30, providing runway into 1Q 2025.
RLYB212 Phase 1b proof-of-concept met endpoint; multiple-dose cohort data and tox results expected in 4Q 2023.
RLYB116 Phase 1 MAD study initial data (safety, PK, PD) and indication strategy expected in 4Q 2023.
Effective Aug 1, Stephen Uden became CEO; Martin Mackay appointed Executive Chairman.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rallybio Corp reported the second quarter ended June 30, 2023 results: net income Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46, EPS $0.46.

Period: the second quarter ended June 30, 2023
Net income: Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46
EPS: $0.46
Result: reported results

Exact text from the filing

On August 8, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001739410-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.